These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36036169)

  • 21. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
    Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
    Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
    Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
    Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
    Gallagher JC; Shi H; Mirkin S; Chines AA
    Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.
    Black D; Messig M; Yu CR; Assaf AR; Komm BS; Mirkin S; Boucher M
    Menopause; 2016 Apr; 23(4):376-82. PubMed ID: 26694733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.
    Mirkin S; Ryan KA; Chandran AB; Komm BS
    Maturitas; 2014 Jan; 77(1):24-31. PubMed ID: 24246155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
    Pickar JH; Lavenberg J; Pan K; Komm BS
    Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies.
    Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L
    Menopause; 2017 Dec; 24(12):1378-1385. PubMed ID: 28654628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
    Kagan R; Abreu P; Andrews E
    Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
    Archer DF; Lewis V; Carr BR; Olivier S; Pickar JH
    Fertil Steril; 2009 Sep; 92(3):1039-1044. PubMed ID: 19635614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.
    Taylor HS; Ohleth K
    Menopause; 2012 Apr; 19(4):479-85. PubMed ID: 22278343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
    Mirkin S; Komm B; Pickar JH
    Womens Health (Lond); 2014 Mar; 10(2):135-46. PubMed ID: 24601804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
    Mirkin S; Komm BS; Pan K; Chines AA
    Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP
    Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV; Stovall DW
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
    Tella SH; Gallagher JC
    Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.
    Stevenson JC; Chines A; Pan K; Ryan KA; Mirkin S
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2329-38. PubMed ID: 25894963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.